Laurel Wealth Advisors (North Carolina)’s Esperion Therapeutics ESPR Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,500	Closed	-$9.25K	–	332
2025 Q4	$9.25K	Buy	+2,500	New	+$8.08K	﹤0.01%	493
2025 Q2	–	Sell	-2,500	Closed	-$3.6K	–	336
2025 Q1	$3.6K	Hold	2,500	–	–	﹤0.01%	565
2024 Q4	$5.5K	Hold	2,500	–	–	﹤0.01%	542
2024 Q3	$4.13K	Hold	2,500	–	–	﹤0.01%	535
2024 Q2	$5.55K	Hold	2,500	–	–	﹤0.01%	472
2024 Q1	$6.7K	Hold	2,500	–	–	﹤0.01%	466
2023 Q4	$7.47K	Hold	2,500	–	–	﹤0.01%	423
2023 Q3	$2.45K	Hold	2,500	–	–	﹤0.01%	502
2023 Q2	$3.48K	Hold	2,500	–	–	﹤0.01%	486
2023 Q1	$3.98K	Hold	2,500	–	–	﹤0.01%	474
2022 Q4	$15.6K	Hold	2,500	–	–	﹤0.01%	352
2022 Q3	$17K	Hold	2,500	–	–	﹤0.01%	346
2022 Q2	$16K	Hold	2,500	–	–	﹤0.01%	348
2022 Q1	$12K	Hold	2,500	–	–	﹤0.01%	392
2021 Q4	$13K	Hold	2,500	–	–	﹤0.01%	385
2021 Q3	$30K	Hold	2,500	–	–	0.01%	305
2021 Q2	$53K	Hold	2,500	–	–	0.01%	274
2021 Q1	$70K	Hold	2,500	–	–	0.02%	236
2020 Q4	$65K	Sell	2,500 -240	-9%	-$7.19K	0.02%	236
2020 Q3	$102K	Buy	2,740 +2,500	+1,042%	+$99K	0.03%	178
2020 Q2	$12K	Hold	240	–	–	﹤0.01%	359
2020 Q1	$8K	Hold	240	–	–	﹤0.01%	380
2019 Q4	$14K	Hold	240	–	–	﹤0.01%	355
2019 Q3	$9K	Hold	240	–	–	﹤0.01%	390
2019 Q2	$11K	Hold	240	–	–	﹤0.01%	364
2019 Q1	$10K	Hold	240	–	–	﹤0.01%	368
2018 Q4	$11K	Buy	+240	New	+$11.6K	﹤0.01%	340

Other funds holding ESPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s ESPR Position: Q1 2026 in Review

Laurel Wealth Advisors (North Carolina) sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 2,500 shares — an estimated $9.25K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in ESPR in Q4 2018 and held it in 27 quarters. The position peaked at $102K in Q3 2020. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

Laurel Wealth Advisors (North Carolina) reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 2,500 Esperion Therapeutics shares in Q1 2026, an estimated $9.25K.
Laurel Wealth Advisors (North Carolina) first reported a position in Esperion Therapeutics in Q4 2018 and held it in 27 quarters.
Laurel Wealth Advisors (North Carolina)'s Esperion Therapeutics position peaked at $102K in Q3 2020.
207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2026, filed 13 May 2026.